Next Article in Journal
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Previous Article in Journal / Special Issue
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
Article Menu

Export Article

Open AccessReview
Antibodies 2017, 6(4), 17;

Therapeutic and Diagnostic Antibodies to CD146: Thirty Years of Research on Its Potential for Detection and Treatment of Tumors

Inserm UMR-S 1076, Aix-Marseille Université, UFR de Pharmacie, 27 Bd J. Moulin, 13005 Marseille, France
Author to whom correspondence should be addressed.
Received: 2 October 2017 / Revised: 26 October 2017 / Accepted: 1 November 2017 / Published: 5 November 2017
(This article belongs to the Special Issue Cancer Antibodies)
Full-Text   |   PDF [918 KB, uploaded 15 November 2017]   |  


CD146 (MCAM, MUC18, S-Endo1) is a transmembrane glycoprotein belonging to both CAM and mucin families. It exists as different splice variants and is cleaved from the membrane by metalloproteases to generate a soluble form. CD146 is expressed by numerous cancer cells as well as being one of the numerous proteins expressed by the vascular endothelium. It has also been identified on smooth muscle cells, pericytes, and some immune cells. This protein was initially described as an actor involved in tumor growth and metastatic dissemination processes. Some recent works highlighted the role of CD146 in angiogenesis. Interestingly, this knowledge allowed the development of therapeutic and diagnostic tools specifically targeting the different CD146 variants. The first anti-CD146 antibody designed to study the function of this molecule, MUC18, was described by the Pr. J.P. Jonhson in 1987. In this review, we will discuss the 30 following years of research focused on the detection, study, and blocking of this protein in physiological and pathological processes. View Full-Text
Keywords: cancer; CD146; antibody; therapy; diagnosis cancer; CD146; antibody; therapy; diagnosis

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Stalin, J.; Nollet, M.; Dignat-George, F.; Bardin, N.; Blot-Chabaud, M. Therapeutic and Diagnostic Antibodies to CD146: Thirty Years of Research on Its Potential for Detection and Treatment of Tumors. Antibodies 2017, 6, 17.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top